Shanghai Institute of Material Medical Chinese Academy of Sciences

Biography

Dr. LIU Hong’s efforts mainly dedicate to the research of medicinal chemistry and drug design and discovery. She is also focusing on the development of new organic synthetic methodologies, building focused combinatorial libraries, and the discovery and optimization of lead compounds for new drugs. Dr. Hong Liu has published 390 academic papers in peer-review journals, such as Science, Chemical Reviews, Angewandte Chemie International Edition, Journal of Medicinal Chemistry, Chemical Communications, Green Chemistry, ACS Catalysis, Organic Letters, etc. Dr. Liu wrote 14 books as chapter author as well and applied 280 patents. She has received many prizes such as the 21st Wu Jieping-Paul Janssen Medicinal & Pharmaceutical Award, Innovative Talent Promoting Program -Innovation Teams in Selected Areas of Priority, the 14th Science and Technology Award for Chinese Youth, the 6th National Excellent Scientific and Technical Workers, the 8th Chinese Young Women in Science Award, the National Science Fund for Distinguished Young Scholars, etc.

Education

1987.09-1991.07, B.S. in Medicinal Chemistry, China Pharmaceutical University

1993.09-1996.07, M.S in Medicinal Chemistry, China Pharmaceutical University

1996.09-1999.07, Ph.D. in Medicinal Chemistry, China Pharmaceutical University

Work Experience

1991.09-1993.08, Assistant Engineer, Shandong Xinghua Pharmaceutical Company

1999.08-2001.08, Post-doctor, Shanghai Institute of Materia Medica, Chinese Academy of Sciences

2002.02-2002.10, Visiting Professor, Department of Pharmacology and Toxicology, University of Texas Medical Branch

2005.01-2005.10, Visiting Professor, Department of Pharmacology and Toxicology, University of Texas Medical Branch

2001.09-2006.06, Associate Professor and Master's supervisor, Shanghai Institute of Materia Medica, Chinese Academy of Sciences

2006.07-present, Professor and doctoral supervisor, Shanghai Institute of Materia Medica, Chinese Academy of Sciences

Research Directions

1. Medicinal Chemistry

2. Organic Synthetic Methodologies

3. Innovative Drug Discovery

4. Computer Aided Drug Design and Molecular Modeling

Grants & Research Projects

1.The National Natural Science Foundation of China, The role of Sphingosine 1-phosphate on the metabolic abnormity of lipid in cancer and the exploration of the regulating mechanisms of critical condition of conversion from inflammation to cancer, Project Leader, 2013.01-2016.12

2. National S&T Major Projects, The preclinical R&D for drug candidate LJN of anti-diabetes, Project Leader, 2012.01-2015.12

3. The National Science Fund for Distinguished Young Scholars, Medicinal chemistry, Project Leader, 2011.01-2014.12

4. F7 EU Framework Programme, Small-molecule inhibitor leads versus emerging and neglected RNA viruses, Project Leader of China, 2010.10-2014.09

Achievements

1. To develop highly effectively synthetic methodologies to construct (chiral) heterocyclic compound libraries

2. To research and develop innovative drugs for some serious diseases

(1) Discovery of DPPIV inhibitor as an anti-diabetic drug

(2) Discovery of AChE inhibitor as an anti-Alzheimer’s disease drug

(3) Discovery of novel anti-BPH (Benign prostatic hyperplasia) drug

(4) Discovery and development of c-Met inhibitors as antineoplastic agents

(5) Discovery and development of CCR5 inhibitors as anti-HIV drug

morefold

Social Titles

1. the Fellow and Senior Member of the Chinese Chemical Society

2. the Associate Editor of the Journal of Medicinal Chemistry

3. the Senior Member of the Chinese Pharmaceutical Association

4. the Editorial Board Member of Bioorganic Medicinal Chemistry Letter, Acta Pharmaceutica Sinica, etc.

morefold

Awards & Honors

The Main Awards

12/2020, The 21st Wu Jieping-Paul Janssen Medicinal & Pharmaceutical Award

07/2020, The 21st China Patent Honorable Mention Award

03/2020, The first prize of Shanghai Pharmaceutical Science and Technology Award

10/2018, Innovative Talent Promoting Program -Innovation Teams in Selected Areas of Priority

05/2016, The 14th Science and Technology Award for Chinese Youth

11/2009, SA-SIBS 2009 Young Faculty Awards

12/2004, Young Chemist Award of Chinese Chemical Society

The Honorary Title

03/2019, 2017-2018 Shanghai Outstanding Female Workers in Science and Technology

11/2014, The 6th National Excellent Science and Technology Workers

09/2014, Zhuli Yuehua Award of Excellent Teachers

09/2012, Excellent Academic Leaders of Shanghai

09/2011, The 8th Chinese Young Women in Science Award

10/2009, The Bearer of Red Flag March 8

morefold

Pubilcations

Full Publication List

Selected Publications

1.Wenhao Dai#, Bing Zhang#, Xia-Ming Jiang#, Haixia Su#, Jian Li, Yao Zhao, Xiong Xie, Zhenming Jin, Jingjing Peng, Fengjiang Liu, Chunpu Li, You Li, Fang Bai, Haofeng Wang, Xi Cheng, Xiaobo Cen, Shulei Hu, Xiuna Yang, Jiang Wang, Xiang Liu, Gengfu Xiao, Hualiang Jiang, Zihe Rao, Lei-Ke Zhang*, Yechun Xu*, Haitao Yang*, Hong Liu*. Structure-Based Design of Antiviral Drug Candidates Targeting the SARS-CoV-2 Main Protease. Science, 2020, 368, 1331-1335.

2.Yichu Liu, Yibing Wang, Wenhao Dai, Wei Huang, Yingxia Li* and Hong Liu*. Palladium-Catalysed C(sp3)-H Glycosylation for Synthesis of C-Alkyl Glycoamino Acids. Angewandte Chemie International Edition, 2020, 59, 3491-3494.

3.Xingjun Li#, Jiang Wang#, Xiong Xie, Wenhao Dai, Xu Han, Kaixian Chen* and Hong Liu*. Ir(III)-Catalyzed direct C–H functionalization of N-phenylacetamide with α-diazo quinones: a novel strategy for producing 2-hydroxy-2’amino-1,2’-biaryl scaffolds. Chemical Communications, 2020, 56, 3441-3444.

4.Xuewu Liang, Jie Zang, Xiaoyang Li, Shuai Tang, Min Huang, Meiyu Geng, C. James Chou, Chunpu Li, Yichun Cao, Wenfang Xu, Hong Liu* and Yingjie Zhang*. Discovery of Novel Janus Kinase (JAK) and Histone Deacetylase (HDAC) Dual Inhibitors for the Treatment of Hematological Malignancies. Journal of Medicinal Chemistry, 2019, 62, 3898-3923.

5.Panfeng Peng#, Huan Chen#, Ya Zhu#, Zhilong Wang#, Jian Li, Rong-Hua Luo, Jiang Wang, Liang Chen, Liu-Meng Yang, Hualiang Jiang, Xin Xie, Beili Wu*, Yong-Tang Zheng* and Hong Liu*. Structure -Based Design of 1？Heteroaryl-1,3-propanediamine Derivatives as a Novel Series of CC-Chemokine Receptor 5 Antagonists. Journal of Medicinal Chemistry, 2018, 61, 9621-9636.

6.Wei Zhu#, Hui Chen#, Yulan Wang#, Jiang Wang, Xia Peng, Xianjie Chen, Yinglei Gao, Yulong He, Jing Ai*, Meiyu Geng, Mingyue Zheng* and Hong Liu*. Design, Synthesis, and Pharmacological Evaluation of Novel Multi-substituted Pyridin-3-amine Derivatives as Multi-Targeted Protein Kinase Inhibitors for the Treatment of Non-Small Cell Lung Cancer. Journal of Medicinal Chemistry, 2017, 60, 6018-6035.

7.Xiaowei Wu, Bao Wang, Shengbin Zhou, Yu Zhou*, and Hong Liu*. Ruthenium-Catalyzed Redox-Neutral [4+1] Annulation of Benzamides and Propargyl Alcohols via C-H Bond Activation. ACS Catalysis, 2017, 7, 2494-2499.

8.Yu Zhou, Jiang Wang, Zhanni Gu, Shuni Wang, Wei Zhu, Jose Luis Acena*, Vadim A. Soloshonok*, Kunisuke Izawa* and Hong Liu*. Next Generation of Fluorine-Containing Pharmaceuticals, Compounds Currently in Phase II？III Clinical Trials of Major Pharmaceutical Companies: New Structural Trends and Therapeutic Areas. Chemical Reviews, 2016, 116, 422-518.

9.Yong Nian, Jiang Wang, Shengbin Zhou, Shuni Wang, Hiroki Moriwaki, Aki Kawashima, Vadim A. Soloshonok* and Hong Liu*. Recyclable Ligands for the Non-Enzymatic Dynamic Kinetic Resolution of Challenging α-Amino Acids. Angewandte Chemie International Edition, 2015, 54, 12918–12922.

10.Jiang Wang, María Sanchez-Rosello, Jose Luis Acena, Carlos del Pozo, Alexander E. Sorochinsky, Santos Fustero*, Vadim A. Soloshonok*, Hong Liu*. Fluorine in Pharmaceutical Industry: Fluorinated Drugs Introduced to the Market in the Last Decade. Chemical Reviews, 2014, 114, 2432-2506.

morefold